Skip to content

Released Jul 30, 2024, before the open

10-Q filed Aug 5, 2024, 36 days after period end · 0000078003-24-000166

Q2 2024 · 10-Q
Revenue$13.28B+2.1% vs Q2 2023−10.7% vs Q1 2024
Net Income$41.00M−98.2% vs Q2 2023−98.7% vs Q1 2024
EPS Diluted$0.01−97.6% vs Q2 2023−98.2% vs Q1 2024
Operating Cash Flowderived-$1,781,000,000N/M
Free Cash Flowderived-$2,418,000,000N/M
Margins · derived
Net margin0.3%−17.6 pt vs Q2 2023

What the release said

The release

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2021
Revenue$13.28B$13.01B$27.74B$18.90B
Net Income$41.00M$2.33B$9.91B$5.56B
EPS Diluted$0.01$0.41$1.73$0.98

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR